Mirati Therapeutics Overview
Mirati Therapeutics Target Price
Analysts' 12-month price predictions for MRTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$58.7
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2022-12-14 | Morgan Stanley | $60 |  2.2% upside |  |
| 2022-12-14 | Leerink Partners | $75 | 27.8% upside | |
| 2022-12-13 | Piper SandlerSwapnil Malekar | $68 | 15.8% upside | |
| 2022-12-13 | Piper Sandler | $87 | 48.2% upside | |
| 2022-12-09 | Citigroup | $53 |  9.7% downside | |
| 2022-12-08 | Leerink Partners | $85 | 44.8% upside | |
| 2022-12-08 | Oppenheimer | $60 | 2.2% upside | |
| 2022-12-08 | J.P. Morgan | $65 | 10.7% upside | |
| 2022-12-07 | BMO CapitalEvan Seigerman | $59 | 0.5% upside | |
| 2022-12-07 | Piper SandlerSwapnil Malekar | $84 | 43.1% upside | |
| 2022-02-01 | Bank of America SecuritiesJason Gerberry | $141 | 140.2% upside | |
| 2021-09-21 | H.C. WainwrightEdward White | $247 | 320.8% upside | |
| 2021-09-20 | JefferiesMaury Raycroft | $193 | 228.8% upside | |